Clinical Trials Logo

Medullary Thyroid Cancer clinical trials

View clinical trials related to Medullary Thyroid Cancer.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT04204928 Approved for marketing - Clinical trials for Non-Small Cell Lung Cancer

Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC

Start date: n/a
Phase:
Study type: Expanded Access

This is a global, multicenter, open-label pre-approval access program to provide access to pralsetinib (BLU-667) until such time that pralsetinib becomes available through other mechanisms or the Sponsor chooses to discontinue the program.

NCT ID: NCT01683110 Approved for marketing - Clinical trials for Medullary Thyroid Cancer

Expanded Access of Cabozantinib in Medullary Thyroid Cancer

Start date: n/a
Phase: N/A
Study type: Expanded Access

The objective of this study is to provide access to cabozantinib for eligible subjects with medullary thyroid cancer (MTC) pending approval of Exelixis' New Drug Application (NDA) by the FDA and commercial availability of cabozantinib.